Pipeline and therapeutic areas
Activity
Activity
We harness our expertise and know-how to provide patients and heath care professionals with medicines that fall within our therapeutic areas while also pursuing an ambitious research and development program.
Pipeline and therapeutic areas
Our brand-name medicines
Cardiometabolism
Atorduo®
Carivalan®
Cosyrel®
Coveram®
Coversyl®
Daflon®
Diamicron®
Lipocomb®
Natrilix®
Natrixam®
Preterax®
Procoralan®
Triplixam®
Triveram®
Vastarel®
Viacoram®
Viacorlix®
Oncology
Asparlas®
Lonsurf®
Muphoran®
Oncaspar®
Onivyde®
Our Medical relief
Emoflon®
Our pipeline
At Servier, we invest nearly 20% of our revenue from brand-name medicines back into research and development, which enables us to maintain a pipeline of innovative projects targeting conditions where there is an as-yet unmet significant medical need. Our pipeline reflects our desire to prioritize the quality and potential of our R&D initiatives. Over 40% of these projects are likely to become first-in-class medicines, which use a new and unique mechanism of action. In December 2024, our pipeline comprised 58 projects, 35 of which in clinical development and 23 research projects.
23
research projects
Data at December 2024
Solid tumors and hematologic malignancies
14
research projects
16
projects in clinical development
Heart failure, Hypertension, Type 2 diabetes, Venous diseases
14
SPCs3 and new formulations
Neurological diseases
7
research projects
2
projects in clinical development
Autoimmune diseases
2
research projects
3
projects in clinical development
Therapeutic areas
We focus our research efforts on indications with significant medical need. Listening to patients enables us to design suitable therapeutic solutions for them in each of our four therapeutic areas.
Given the increasing prevalence of cancer throughout the world (80% rise in cases in people under the age of 50 since 1990 and an estimated 68% rise for people up to the age of 85 by 2040), we have identified oncology as one of our priorities for development. We allocate nearly 70% of our R&D budget to this area, with programs that concentrate on targeted therapies. We are an innovative player in treating rare cancers, especially certain digestive, brain and blood cancers.
Cardiovascular diseases and related complications represent the leading cause of death throughout the world, responsible for claiming the lives of 17.7 million people, or 31% of all deaths. We maintain our leading position in cardiometabolism by taking a strategic and innovative approach to managing the life cycle of our medicines. Our expertise in incremental innovation enables us to make significant progress, especially in treatments that combine several active ingredients in a single pill3. To help patients adhere to their treatment, we also develop innovative digital services to better support them.
We are already looking ahead, positioning ourselves in neurology, and more specifically in neuromuscular and rare movement disorders and refractory epilepsy. In 2021, more than 3 billion people around the world – over a third of the global population – were living with a neurological disorder, making these conditions the world’s biggest cause of illness and invalidity.
Autoimmune diseases affect between 5 to 8% of the world’s population. They provoke an abnormal immune system response that attacks the patient’s own healthy tissues or organs. Our R&D efforts seek to develop treatments that target these diseases with a strong therapeutic need.
(1) Voranigo® was approved in the US in August 2024, as well as in projects involved in the Orbis project (Switzerland, Canada, Israel, Australia) and the United Arab Emirates.
(2) New Molecular Entity
(3) Single Pill Combination (SPC)